The Department of Pharmaceuticals released four schemes in relation to development of bulk drugs and medical device parks to promote domestic manufacturing in pharmaceutical industry. The objective is to make India self-reliant in the production of Active Pharmaceutical Ingredients (APIs) or Key Starting Materials (KSMs) or Drug Intermediates (DIs) and in production of medical devices. The objective is in line with the “Atmanirbhar Bharat” vision of the Indian government.

The medical device industry is highly capital intensive with a long gestation period and requires development and induction of new technologies. Further, domestic medical device market in India is heavily dependent on imports which contribute to more than 85% of the market.  Similarly, India is significantly dependent on import of some of the basic raw materials, viz., bulk drugs that are used to produce the finished dosage formulations. India imports bulk drugs largely for economic considerations. Bulk drugs accounted for 63% of the total pharmaceutical imports in the country during FY 2018-19.

With a view to attain self-reliance and reduce import dependence for medical device industry and pharmaceutical industry, these schemes have been introduced.

Click here to download